Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service LAA occlusion & loop recorders cases in Nebraska: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (229 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 16 | 514 | 18% |
| 2020 | 16 | 590 | 22% |
| 2021 | 22 | 989 | 27% |
| 2022 | 20 | 1,113 | 31% |
| 2023 | 27 | 1,186 | 35% |
| 2024 | 22 | 1,071 | 37% |
| 2025 from claims | – | 1,087 998–1,150 | 37% |
| 2026 forecast | – | 1,197 1,054–1,382 | 37% |
| 2027 forecast | – | 1,312 1,122–1,564 | 37% |
| 2028 forecast | – | 1,438 1,200–1,761 | 38% |
| 2029 forecast | – | 1,576 1,288–1,977 | 38% |
| 2030 forecast | – | 1,728 1,384–2,214 | 38% |
Left atrial appendage closure and implantable loop recorders: an older, Medicare-heavy population. Professional codes (what the surgeon bills): CPT 33340, 33285; the hospital bills MS-DRG 273, 274, 317.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 73% of the cases CMS names in Nebraska; 12 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 71% inpatient hospital, 27% hospital outpatient, 3% office. The share outside the hospital has moved −6 pts since 2019.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Office |
|---|---|---|---|
| 2026 · ~1,200 | ~860 | ~310 | ~26 |
| 2027 · ~1,300 | ~950 | ~340 | ~26 |
| 2028 · ~1,400 | ~1,000 | ~370 | ~27 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 72% (71% in 2025), hospital outpatient about 25% (27% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Illinois | 125 | 4,051+13%/yr | +13%/yr | 2.6 | 15% | 6,990 in 2030+9.5%/yr |
| Ohio | 94 | 3,603+4.6%/yr | +4.6%/yr | 2.8 | 1% | 6,180 in 2030+9.4%/yr |
| Michigan | 82 | 3,065+2.7%/yr | +2.7%/yr | 3.1 | 17% | 4,880 in 2030+8.1%/yr |
| Indiana | 68 | 2,697+18%/yr | +18%/yr | 3.3 | 0% | 4,650 in 2030+9.5%/yr |
| Kansas | 56 | 2,663+15%/yr | +15%/yr | 6.0 | 5% | 4,850 in 2030+10%/yr |
| Missouri | 58 | 2,381+6.1%/yr | +6.1%/yr | 3.3 | 1% | 3,950 in 2030+8.8%/yr |
| Wisconsin | 50 | 1,796+14%/yr | +14%/yr | 2.7 | 0% | 3,250 in 2030+10%/yr |
| Minnesota | 42 | 1,476+9.6%/yr | +9.6%/yr | 2.8 | 3% | 3,650 in 2030+16%/yr |
| Iowa | 21 | 859+11%/yr | +11%/yr | 1.8 | 5% | 1,760 in 2030+13%/yr |
| North Dakota | 15 | 600+12%/yr | +12%/yr | 5.5 | 0% | 1,190 in 2030+12%/yr |
| South Dakota | 11 | 481+17%/yr | +17%/yr | 3.4 | 0% | 890 in 2030+11%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Pacemaker, ICD & CRT implantation | 20 | 1,389−4%/yr | −4%/yr | 5.51.0× | 4% | 1,420 in 2030+0.4%/yr |
| EP ablation | 15 | 802+7.1%/yr | +7.1%/yr | 2.80.9× | 0% | 1,560 in 2030+12%/yr |
LAA occlusion & loop recorders in every state, and its device makers · Every procedure market in Nebraska · Every state · Compare with Illinois
Abbott leads with 91% of company spending on these surgeons in 2025, −5 pts on 2024.
In 2025, 4 companies reported engagement with Nebraska’s surgeons worth $252K in consulting, speaking, meals and travel tied to these products, about $11K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 20 clearances and approvals in the category, 6 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.